Policy brief on improving access to artemisinin-based combination therapies for malaria in the East African community

The World Health Organization (WHO) since June 1998 has advocated for the use of artemisinin-based combination therapies (ACTs) in countries where Plasmodium falciparum malaria is resistant to traditional antimalarial therapies such as chloroquine, sulfadoxine-pyrimethamine, and amodiaquine (19;22)....

Full description

Saved in:
Bibliographic Details
Published in:International journal of technology assessment in health care 2010-04, Vol.26 (2), p.255-259
Main Authors: Nabudere, Harriet, Upunda, Gabriel L., Juma, Malick
Format: Article
Language:English
Subjects:
Africa, Eastern
Antimalarials
Antimalarials - administration & dosage
Antiparasitic agents
Artemisinins - administration & dosage
Burundi
Care access
Communities
Community health care
Developing countries
Drug Therapy, Combination
East African Community
Fever
Guidelines
Health
Health care
Health care access
Health care policy
Health facilities
Health insurance
Health Policy
Health sciences
Health services
Health Services Accessibility
Humans
Kenya
Lactones - administration & dosage
LDCs
Malaria
Malaria - drug therapy
Plasmodium falciparum
Policies
Private sector
Rwanda
Tanzania
Therapy
Uganda
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The World Health Organization (WHO) since June 1998 has advocated for the use of artemisinin-based combination therapies (ACTs) in countries where Plasmodium falciparum malaria is resistant to traditional antimalarial therapies such as chloroquine, sulfadoxine-pyrimethamine, and amodiaquine (19;22). In 2006, WHO released evidence-based guidelines for the treatment of malaria backed by findings from various scientific studies (21). During the period between 2002 and 2006, all the five East African states Tanzania, Kenya, Uganda, Rwanda, and Burundi changed their national antimalarial treatment policies to use ACTs as first-line treatments for uncomplicated falciparum malaria and commenced with deployment of the drugs in the state-managed health facilities (12–15). To scale up the use of ACTs in the East African region to combat malaria and speed up progress toward the sixth Millennium Development Goal, a combination of delivery, financial, and governance arrangements tailored to national or subnational contexts needs to be considered.
ISSN:0266-4623
1471-6348
DOI:10.1017/S026646231000019X